Skip to main content
Home
FULL MENU Close Menu
Home
Home

Walter Alexander

News

Many ED visits may be preventable for NSCLC patients

Author:
Walter Alexander
Publish date: January 19, 2021

Overall, 24% of ED visits were deemed preventable, and 10% were considered unnecessary.

  • Read More

News

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases

Author:
Walter Alexander
Publish date: December 24, 2020

Findings could lead to better monitoring of comorbidities and deeper understanding of disease burden and AD pathophysiology, the authors write.

  • Read More

News

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo

Author:
Walter Alexander
Publish date: December 22, 2020

Phase 3 study shows superior event-free survival and reduced toxicities for blinatumomab versus chemotherapy....

  • Read More

News

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy

Author:
Walter Alexander
Publish date: December 16, 2020

Delayed count recovery remains a key safety concern.

  • Read More

News

Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL

Author:
Walter Alexander
Publish date: December 14, 2020

STAR (synthetic T-cell receptor and antigen receptor) T-cells were reported superior to CAR T cells for acute...

  • Read More

News

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies

Author:
Walter Alexander
Publish date: December 11, 2020

Once-daily oral DTRM-555 shows encouraging activity in Richter’s transformation and DLBCL.

  • Read More

News

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab

Author:
Walter Alexander
Publish date: December 11, 2020

Favorable MRD negativity and overall survival rates with low higher-grade toxicities suggest that reductions in...

  • Read More

News

Rechallenge ‘reasonable’ for some with small-cell lung cancer

Author:
Walter Alexander
Publish date: December 10, 2020

Carboplatin plus etoposide significantly prolonged progression-free survival, compared with topotecan, in patients with advanced or relapsed,...

  • Read More

News

Geography and behaviors linked to early-onset colorectal cancer survival in U.S. women

Author:
Walter Alexander
Publish date: December 9, 2020

Physical inactivity and lower fertility correlate modestly with early-onset colorectal cancer mortality in women.

  • Read More

News

Phase 1 study: Beta-blocker may improve melanoma treatment response

Author:
Walter Alexander
Publish date: December 8, 2020

“It’s exciting that an extremely inexpensive drug like propranolol that could be used in every country around the world could have an impact on...

  • Read More

News

Fixed duration ibrutinib/venetoclax appears feasible for some CLL/SLL patients

Author:
Walter Alexander
Publish date: December 6, 2020

After 12 cycles of ibrutinib/venetoclax, patients then randomized to placebo had 1-year disease-free survival of...

  • Read More

News

TNF inhibitor–induced psoriasis treatment algorithm maintains TNF inhibitor if possible

Author:
Walter Alexander
Publish date: November 25, 2020

TNFI-induced psoriasis improved or resolved with topical medications alone in 63.5% of patients.

  • Read More

News

Adding cetuximab to afatinib provides no benefit in EGFR-mutant NSCLC

Author:
Walter Alexander
Publish date: November 5, 2020

Survival outcomes were similar whether patients received afatinib alone or afatinib plus cetuximab.

  • Read More

News

No benefit with adjuvant sorafenib in intermediate-/high-risk RCC

Author:
Walter Alexander
Publish date: November 2, 2020

Survival was similar with adjuvant sorafenib and placebo.

  • Read More

News

Baricitinib reduces adult atopic dermatitis severity in phase 3 study

Author:
Walter Alexander
Publish date: October 20, 2020

In moderate to evere AD, baricitinib 4 mg on top of topical corticosteroids significantly reduced signs and symptoms.

  • Read More

Pages

  • 1
  • 2
  • last »

Privacy Policy

Do Not Sell My Personal Information

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close